Desarrollo clínico de ABIRATERONA
Localized
Disease
m0CRPC
mCRPC
L
1
mCRPC
L
N
mCRPC
L
N+1
m1HNPC
Biochemical
recurrence
Ph2 Neoadj AA+GnRH agonist in High Risk (COU-AA-203)
Ph2 AA + Different Steroid Regimens
Ph2 ABIDO
AA+ docetaxel after
progression on AA
Ph3 M1 LATITUDE
ADT+/-AA in High-Risk, Metastatic Hormone-Naive PC
Ph3b Multicenter, Open-label Abiraterone Acetate Long-term
Safety Study
Ph2 AA+RT+Short-Term Androgen Deprivation in
Unfavorable Risk Localized PC
Ph2 AA+ENZ in High-Risk for Recurrence
Ph3 PEACE 1
ADT+/-AA+/-RT Metastatic Hormone-Naive PC
Ph3 BAYER Radium-223 +/-AA
Ph2 SPARE
AA+LHRH vs AA sparing LHRH theraphy
Ph2 CARLHA
AA+RT+6 months LH-RH agonist in
Biochemically-relapsing PC Following
Surgery
Ph3 STAMPEDE
Systemic theraphy in Advancing or
metastatic PC
Ph2 neoadj AA
in High Risk (COU-AA-201)
Ph2 horm+RT+/-RT very high risk
Ph2 IMAAGEN
ADT+/-AA in High-Risk,
M0 CPRC
